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ABSTRACT
Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome 
(NS) cases. Adult-MCD patients may have more severe clinical features than pediatric 
patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently 
relapsing NS. In adults, data about the efficacy of RTX for MCD are limited. We report 
our experience on the use of RTX in adult biopsy-proven MCD. Our series includes 6 
adult patients (2 males and 4 females), age 45–73 years, treated with RTX (4 weekly 
doses of 375 mg/m2). Proteinuria decreased from 11,2 (23–4.8) g/24 hours to 0.6  
(0–2) g/24 hours after 6 months, and to 0.4 (0–1, 4) g/24 h in the 4 pts with the longer 
follow-up. Creatinine decreased from 1.95 (0.5–5) mg/dl to 0.88 (0.6–1.3) mg/l.  
Five patients achieved a complete renal remission, while in 1 pt proteinuria decreased 
by 75%. RTX successfully depleted CD19 lymphocytes in 100% of pts for at least  
6 months. No clinically relevant adverse events have been observed. This case series 
shows a remarkable efficacy of RTX in treatment of MCD. RTX can be an attractive 
alternative both in recurrent forms and in induction-therapy of MCD. RTX may be 
preferentially used in patients at a high risk of development of the adverse effects 
of corticosteroids and should be considered as an alternative option in patients with 
recurrent NS. Additional data are needed to inform clinical practice on how best to 
use RTX in this patient population, so that definitive randomized trials can be planned.
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INTRODUCTION
Minimal change disease accounts for 15% of adult 
cases of nephrotic syndrome [1].
Because of its high prevalence in children, most 
studies on the natural course, treatment, and prognosis of 
MCD have focused on pediatric population. Although the 
exact etiology of MCD remains unknown, dysregulation 
of the immune system is thought to be an important factor 
in pathogenesis [2]. In general, MCD is considered a self-
limiting and relatively benign disease, and the risk of end-
stage renal disease (ESRD) is extremely low. On the other 
hand, adult-onset MCD patients (pts), especially those 
who are found to have focal segmental glomerulosclerosis 
(FSGS) on a second kidney biopsy, might experience a 
progression to ESRD [3]. Adult-onset MCD patients may 
have more severe clinical features than pediatric MCD pts. 
Remission induction is of great relevance to these patients. 
Significant practice variability exists in the management of 
adult MCD [4]. Several therapeutic approaches have been 
attempted in nephrotic adult-MCD, but the best treatment, 
able to assure rapiddly induced, long time remission 
with few adverse events, is far from being established. 
There are only few randomized clinical trials (RCTs) 
addressing therapy for these conditions in adults. Steroids 
are the mainstay of treatment. Glucocorticosteroids have 
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been recommended as a first-line therapy by the Kidney 
Disease Improving Global Outcomes (KDIGO) guidelines 
[5]. Adult-onset MCD patients have been reported to be at 
higher risk of acute kidney injury with delayed response to 
glucocorticosteroids as compared to pediatric pts [6]. Only 
30% of adult pts achieve remission over the 8 week course 
of therapy which is thought to be sufficient in the majority 
of pediatric cases. Furthermore, among adults who do 
respond to corticosteroid therapy, 25% will experience 
a frequent relapsing course and 30% become steroid-
dependent [7]. Repeated and prolonged steroid therapy is 
associated to a number of side effects [8].
A variety of approaches to the management of MCD 
have been attempted. Immunosuppressive (IS) agents, 
such as calcineurin-inhibitors [9], cyclophosphamide 
[10] and mycophenolate mofetil [11], have been used. 
Cyclosporin-A is usually effective, but relapses often occur 
after therapy discontinuation. Moreover, the administration 
of calcineurin-inhibitors is frequently associated with renal 
dysfunction, hypertension, hyperlipidemia and gingival 
hyperplasia [12, 13]. Mycophenolate-mofetil may reduce 
the frequency of relapses, but its use can be limited by 
gastrointestinal adverse effects. Cyclophosphamide may 
induce long term remission of MCD in about 50% of 
patients, but cytotoxicity and infertility limit its use.
Rituximab (RTX) has been employed in children 
since 2006 in order to treat frequently relapsing NS [14]. 
RTX is currently approved for the treatment of CD20-
positive lymphoma, rheumatoid arthritis and ANCA-
associated vasculitides [15]. It is increasingly being used 
off-label in a variety of autoimmune and renal disorders 
[16] such as membranous nephropathy [17, 18] and IgA 
vasculitis [19]. While data regarding the efficacy of 
RTX in adult MCD are limited, it seems to be effective 
in reducing frequency of relapses and concomitant 
immunosuppression in 65–85% of patients [20]. However, 
different dosage and regimen (single flat dose of 500; 
1,000 mg at 1 or 2 time-points, or 375 mg/m2 once weekly 
for 4 weeks), mixed populations (steroid-dependent and/
or steroid-resistant patient samples) and diverse scheme 
(induction or maintenance) make RTX effects difficult to 
interpret. Whether RTX is best used to induce or maintain 
remission and in which pts, whether repeated doses 
improve response rate, and which protocol should be used 
remain to be established.
Herein we describe the effects of RTX given alone 
as a front induction therapy in a series of adult biopsy-
proven MCD patients.
RESULTS
Mean age of the patients was 62.7 years 
(min 45–max 73) (Table 1). All pts were treated with RTX 
as first-line therapy. Three pts reached a complete remission 
within 3 months, 1 pt within 6 month, and 1 pt within 
9 months. In these pts, the complete remission persisted 
during the entire follow-up period. In the remaining pt (pt # 
4) the decrease in urinary protein excretion was >75% after 
9 months (Figure 1) and remained unchanged after 1 year.
A significant increase in serum albumin and IgG 
levels were found during follow-up as compared to the 
baseline values (Table 2). Three pts had an impaired renal 
function at the diagnosis. In 2 of them, creatinine values 
normalized within 1 month after RTX administration and 
in the 3th pt (#5) within 3 months. None of these patients 
relapsed during the follow-up of 8–36 months.
With regards to the safety, none of the 6 pts 
experienced infusion-related or hematological reactions, 
nor developed infections by the end of follow-up.
DISCUSSION
Many therapeutic approaches for adult MCD have 
been attempted, but the ideal regimen is far from being 
established. In contrast to the known involvement of T 
cells in minimal-change nephrotic syndrome (MCNS), 
the role of B-lymphocytes is not defined yet [21]. B-cell 
biology, however, has attained attention since RTX, a 
monoclonal antibody directed to CD20-bearing cells, 
has shown some therapeutic response in the treatment of 
MCD. In recent years, it has been reported that B-cells 
also have regulatory functions. The regulatory B-cell 
stimulates both effector and regulatory T-cells [22]. In 
other auto-immune diseases, regulatory T-cell function 
improves after treatment with RTX [18, 23]. The 
mechanism of action is unknown, B-cell depletion may 
lead to a new balance between the T-cell subsets. This 
balance can be established even after repopulation of the 
peripheral B-cells. A possible mechanism is that T-cells 
that interact with B-cells are removed simultaneously after 
treatment with RTX [24, 25].
Previous findings have shown that CD23 increases 
in patients with nephrotic syndrome [26]. Recent studies 
have reported that increased Interleukin-13, a cytokine 
associated with type 2 T-helper cells, can lead to podocyte 
injury and may induce a MCNS-like phenotype [27]. 
B-cells are essential in CD4 T-cell activation for antigen 
presenting and providing co-stimulation signals. Tokunaga 
et al. [28] showed that RTX decreases CD40- and CD80-
expression in activated B-cells in patients with systemic 
lupus-erythematosus, and down-regulates CD40L and 
CD69 on CD4-positive cells. Successful induction of 
remission following RTX treatment in some cases of 
MCD provides evidence that the interference of B- and 
T-cells is a potential strategy for MCD treatment [29]. On 
the other hand, it is also possible that the B-cells play a 
direct role in the pathogenesis of MCD, but evidence of 
this hypothesis is lacking. Moreover, RTX directly affects 
T-cells, affecting naïve/memory balance [30]. Beside 
immunological explanation, RTX may exert a direct effect 
in the kidney. A recent study shows that RTX may stabilize 
the cytoskeleton of the podocyte [31].
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Table 1: Demographic and clinical baseline characteristics of patients
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6
Sex F M M F F F
Age at diagnosis
(years)
45 59 72 61 73 66
Duration of 
follow-up 
(months)
36 34 30 12 8 9
Urinary protein 
(g/day)
4.8 5.6 23 5.5 22 9,6
Albumin (g/dL) 2.1 2.3 1.3 2.9 1.7 2
Total cholesterol 
(mg/dL)
347 325 416 468 208
Creatinine 
(mg/dL)
0.8 1.6 3.2 0.5 5 0.6
White blood cell 
count (u/mm3)
4.280 8.280 6.210 8.930 9420 7190
Lymphocytes 
(×1000/ul)
1070 1010 1480 1420 603 2380
CD19 (/mm3) 77 (7.19%) 42 (4.15%) 148 (10%) 258 (12.8%) 96 (16%) 229 (8.3%)
CD20 (/mm3) 77 (7.17%) 42 (4.15%) 145 (9.84%) 255 (12.7%) 96 (16%) 229 (8.3%)
IgG (mg/dL) 373 794 229 1414 184 537
IgA (mg/dL) 124 137 181 130 152 146
IgM (mg/dL) 221 42 99 37 298 165
Figure 1: Evolution of proteinuria.
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To our knowledge this is the first report of 
adult minimal change disease treated with RTX as 
first-line therapy without the association of steroid/
immunosuppressive drugs. All patients met the clinical 
criteria of nephrotic syndrome although in some of 
them proteinuria values were not so high as commonly 
expected. Three patients had a renal failure. The minimal 
change disease was biopsy proven in all patients. In our 
cohort, one patient had a partial remission and 5 patients 
had complete response within 6 months, and remained in 
remission at the end of follow-up after a single course of 
anti-CD20 therapy (median follow-up 21.5 months, 8–36 
months). We cannot exclude by certainty that the patients 
could experience a spontaneous remission. Actually, 
every patient did respond to the RTX regimen with a time 
to remission consonant with the effectiveness timing of 
the drug.
An unanswered question is whether RTX treatment 
should be repeated after repopulation of the peripheral 
B-cell population in the effort to achieve protracted 
remission. Published studies vary with regard to the dose 
and number of doses of RTX that are needed to achieve 
long-term remission of MCD. A single dose of RTX 
achieved a good response in the series of 12 patients 
described by Kamei, but the relapse rate was 75% [32]. 
Another study found that the time to NS relapse was 
longer when more than three doses were given at the 
beginning [33].
In our series, 5 patients experienced a sustained 
remission over a prolonged follow-up and did not required 
repeated infusions. They remained relapse-free despite 
the recovery of B-cell count, suggesting that, as in other 
immunologic disorders [18, 26], RTX restores patients’ 
immunologic balance. This data differs from previous 
experiences reported in literature. Protracted remission 
could be due to the greater dose regimen (4 doses of 375 
mg/m2) we used compared to other published series.
Other possible explanations include the characteristics 
of our patient sample which differ from previous studies, 
i.e., older age and naive cases compared to steroid-
dependent and frequent relapsing forms.
Further studies are needed to confirm this 
hypothesis.
MATERIALS AND METHODS
We describe the effects of the treatment with 
RTX in a cohort of six adult patients with biopsy-
proven MCD. The kidney histology was normal and the 
immunofluorescence negative; the electron microscopy 
was not done in all patients. Secondary causes were 
carefully ruled out. All patients received RTX as first 
line-therapy, without the association of corticosteroids 
or any other immunosuppressive agents. All the patients 
were treatment naive. They were treated with 4 doses of 
375 mg/m2 RTX with a 1-week interval. All patients had 
definite contraindications to steroid therapy (diabetes, 
BMI > 30, psychosis). All patients had a nephrotic 
syndrome. Renal function was normal in 3 pts, while the 
other 3 had renal impairment. The pressure values were 
normal and none of them was tacking RAS blockade. The 
clinical characteristics of the patients at baseline and at last 
follow-up are summarized in Tables 1 and 2. Laboratory 
parameters, including hepatitis-C and hepatitis B markers 
(hepatitis-B surface antigen and antibody, and hepatitis-B 
core antibody) were detected in all patients. Two pts who 
were Quantiferon-TB positive, despite the absence of 
other signs of disease. They were treated with isoniazid 
for 6 months.
CONCLUSIONS
The major limitations of the study include its 
retrospective nature and the small sample. Nevertheless, 
Table 2: Laboratory data at last follow-up
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6
Urinary protein 
(g/day) 0 0.1 0.1 1.3 0.15 0
Albumin (g/dL) 4.2 3.9 4.5 3.2 4.3 3.6
Creatinine 
(mg/dL) 0.8 0.9 0.8 0.6 1.2 0.6
White blood cell 
count (u/mm3) 4.360 7740 9700 12330 5500 7190
Lymphocytes 
(×1000/ul) 1170 1160 2910 1190 2250 2380
IgG (mg/dL) 778 1079 987 1378 740 840
IgA (mg/dL) 148 137 178 147 152 140
IgM (mg/dL) 110 45 70 34 248 145
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our results support the encouraging effects reported in a 
pediatric setting. We suggest that RTX, given alone, is an 
effective and safe front-line therapy in adult patients with 
MCD. RTX might be preferred in patients at high risk of 
developing the several adverse effects of corticosteroids. 
Our study sets the scene for future large-scale prospective 
studies to further investigate the use of RTX in the context 
of the management of adult onset of minimal change 
disease.
Abbreviations
MCD: minimal change disease; NS: nephrotic 
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